



Prospective Evaluation of ResistancePlus MG, a New Multiplex Quantitative PCR Assay for Detection of *Mycoplasma genitalium* and Macrolide Resistance

S. N. Tabrizi,^{a,b,c} J. Su,^{a,b} C. S. Bradshaw,^{d,e} C. K. Fairley,^{d,e} S. Walker,^f L. Y. Tan,^f E. Mokany,^f S. M. Garland^{a,b,c}

Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia^a; Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia^b; Murdoch Childrens Research Institute, Parkville, Victoria, Australia^c; Melbourne Sexual Health Centre, Carlton, Victoria, Australia^d; Central Clinical School, Monash University, Frankston, Victoria, Australia^e; SpeeDx Pty Ltd., Sydney, NSW, Australia^f

ABSTRACT *Mycoplasma genitalium* is a significant pathogen for which first-line treatment is becoming less effective due to increased resistance to macrolides. As conventional culture and antimicrobial susceptibility testing is not feasible for routine detection of this pathogen, molecular markers such as detection of mutations in the 23S rRNA gene have been described to predict resistance. Recently, a novel multiplex quantitative PCR (qPCR) assay, ResistancePlus MG, has been described for the simultaneous detection of *Mycoplasma genitalium* and macrolide resistance. In the current study, the clinical performance of the assay was evaluated on 1,089 consecutive urine and anogenital swab samples in symptomatic and asymptomatic male and female patients. Overall, 6.0% were positive for *M. genitalium*, with 63.1% having macrolide resistance-associated mutations. Compared to the laboratory-validated qPCR method targeting the 16S rRNA gene and Sanger sequencing to determine 23S rRNA mutations, the sensitivity and specificity of *M. genitalium* detection were 98.5% and 100% and for detection of macrolide resistance mutations were 100.0% and 96.2%, respectively. This assay offers a considerable advantage in clinical settings for *M. genitalium* testing by making the results of macrolide resistance and mutation analyses simultaneously available, which is increasingly important with escalating macrolide resistance.

KEYWORDS *Mycoplasma genitalium*, macrolide resistance, 23S rRNA, multiplex assay, NAAT, qPCR, diagnostic, sensitivity and specificity

Mycoplasma genitalium is a significant pathogen in the etiology of nongonococcal urethritis (NGU) in men (1, 2) and of cervicitis, pelvic inflammatory disease (PID), and infertility in women (3–7). Infections and syndromes associated with *M. genitalium* such as NGU are often treated with the macrolide antibiotic azithromycin (8, 9). However, over the past decade, there have been increasing reports of declining cure rates, which in some settings are now as low as 50% in genital *M. genitalium* infections in symptomatic men and women (10–13). Azithromycin treatment failure is strongly associated with the presence of mutations in binding region V of the *M. genitalium* 23S rRNA gene (equivalent to *Escherichia coli* nucleotide positions 2058 and 2059) (11, 14).

M. genitalium is a fastidious, slow-growing organism and is challenging to culture. Therefore, traditional culture-based methods are not possible for routine diagnosis; hence, detection requires nucleic acid amplification tests (NAATs). Conventional culture-based antibiotic susceptibility tests are therefore also not feasible.

Received 18 November 2016 **Returned for modification** 16 December 2016 **Accepted** 2 April 2017

Accepted manuscript posted online 5 April 2017

Citation Tabrizi SN, Su J, Bradshaw CS, Fairley CK, Walker S, Tan LY, Mokany E, Garland SM. 2017. Prospective evaluation of ResistancePlus MG, a new multiplex quantitative PCR assay for detection of *Mycoplasma genitalium* and macrolide resistance. *J Clin Microbiol* 55:1915–1919. <https://doi.org/10.1128/JCM.02312-16>.

Editor Sandra S. Richter, Cleveland Clinic

Copyright © 2017 Tabrizi et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to S. N. Tabrizi, sephr@unimelb.edu.au.

TABLE 1 Specimen types and reference assay results

Assay result	No. (%) of specimens						Total
	Male			Female			
	Urine/urethral	Anal swab	All	Urine	Vaginal/cervical/rectal swab	All	
<i>M. genitalium</i>							
Detected	35 (9.9)	7 (20.6)	42 (10.8)	14 (6.9)	9 ^a (1.8)	23 (3.3)	65 (6.0)
Not detected	319 (90.1)	27 (79.4)	346 (89.2)	189 (93.1)	489 (98.2)	678 (96.7)	1,024 (94.0)
Total	354 (100)	34 (100)	388 (100)	203 (100)	498 (100)	701 (100)	1,089 (100)
23S rRNA status							
Wild type	8 (22.9)	0 (0)	8 (19.0)	12 (85.7)	4 (44.4)	16 (69.6)	24 (36.9)
Mutant ^b	27 (77.1)	7 (100)	34 (81.0)	2 (14.3)	5 ^a (55.6)	7 (30.4)	41 (63.1)
Total	35 (100)	7 (100)	42 (100)	14 (100)	9 (100)	23 (100)	65 (100)

^aIncludes one rectal sample from a female.

^bMutations included 23 A2058G, 13 A2059G, 4 A2058T, and 1 A2058C.

However, prediction of resistance can be inferred from the detection of the macrolide resistance-mediating mutations in the 23S rRNA gene (13, 14).

Different NAATs have been utilized for the detection of macrolide resistance mutations. DNA sequencing has been used to detect mutations in cases of treatment failure and is also the gold standard method for mutant determination (14). Sequencing, however, is generally not feasible for routine diagnosis due to the higher cost and longer turnaround time to results, delaying the reporting of macrolide resistance and hence treatment with second-line antimicrobials. Alternatively, other real-time quantitative PCR (qPCR)-based approaches have been utilized such as high-resolution melt assay (HRMA)-based methods (15, 16), a 5' nuclease assay, and the use of mutation-specific primers (17, 18). These methods were limited in their ability to detect the macrolide resistance mutations in all *M. genitalium*-positive samples or were restricted in sensitivity and the ability to multiplex. These methods have been demonstrated only on *M. genitalium*-positive samples, with the exception of the fluorescence resonance energy transfer (FRET) method; however, this was limited in sensitivity for *M. genitalium* detection (19).

ResistancePlus MG is a new multiplex qPCR assay employing novel PlexZyme and PlexPrime technology (Speedx Pty Ltd., Sydney, Australia) that has recently been developed (20) and that allows simultaneous detection of *M. genitalium* and the common mutations associated with macrolide resistance (including A2058G, A2059G, A2058T, A2058C, and A2059C) in one well (21). The previous evaluation assessed clinical performance in an infected population and also analytical performance (21). In this study, a prospective clinical evaluation of this assay was conducted in a routine clinical setting, thereby reflecting the prevalence of *M. genitalium* and mutations associated with macrolide resistance in this population. The performance of the assay for both *M. genitalium* detection and determination of mutation status was compared to that of a laboratory-validated qPCR method targeting the 16S rRNA gene and Sanger sequencing of the 23S rRNA gene.

RESULTS AND DISCUSSION

The specimens included 388 samples comprising 354 urine/urethral swabs and 34 anal swabs from men and 701 samples comprising 203 urine and 497 cervical/vaginal swabs and 1 rectal swab from women (Table 1).

Overall, 6.0% (65/1,089) of the samples were positive for *M. genitalium* by the reference 16S rRNA gene assay, with 10.8% of male and 3.3% of female samples being positive. A 23S rRNA mutation was detected in 63.1% (41/65) of the positive samples by Sanger sequencing (Table 1). A total of 34 (81.0%) samples from males had macrolide resistance mutations compared to 7 (30.4%) samples from females ($P < 0.0001$). Overall, the prevalence of *M. genitalium* and macrolide-resistant mutations was significantly higher in men ($P < 0.0001$), as they were primarily from symptomatic patients at the

TABLE 2 Evaluation of the ResistancePlus MG assay for the detection of *M. genitalium* and 23S rRNA gene mutations^a

Parameter	ResistancePlus MG result	Reference assay result (no. of specimens) ^b			% sensitivity (95% CI)/% specificity (95% CI) (negative predictive value [95% CI]/positive predictive value [95% CI])
		Pos	Neg	Total	
<i>M. genitalium</i>	Pos	64	0	64	98.5 (91.7–99.9)/100 (99.6–100) (99.9 [99.5–100]/100 [94.4–100])
	Neg	1 ^c	1,024	1,025	
23S rRNA mutation	Detected	38	1	39	100 (90.8–100)/96.2 (80.4–99.9) (100 [86.3–100]/97.4 [86.5–99.9])
	Not detected	0	25	25	

^aPos, positive; Neg, negative.

^bThe reference assay used for *M. genitalium* detection was a standard assay in use in the laboratory (22, 23), and the assays used for 23S rRNA mutation status detection were Sanger sequencing and HRMA (14, 16). In the comparison of mutation detection results, Pos by the reference assay represents detection of a mutant strain and Neg represents detection of the wild-type strain.

^cFewer than 100 copies of *M. genitalium* were detected in the sample.

Melbourne Sexual Health Centre (MSHC), Victoria, Australia. It is noteworthy that macrolide resistance mutations were detected in all *M. genitalium*-positive rectal swabs, highlighting a particularly challenging issue in treatment of rectal infections.

The level of concordance of the ResistancePlus MG assay with the reference method for detection of *M. genitalium* was 99.9%, with a Kappa value of 0.99 (95% confidence interval [CI], 0.98 to 1.00) and sensitivity and specificity of 98.5% and 100.0%, respectively. In this routine clinical setting, the positive and negative predictive values for detection of *M. genitalium* were 100% and 99.9% and the positive and negative predictive values for detection of 23S rRNA mutations were 97.4% and 100%, respectively (Table 2). Overall, only 1 discordant *M. genitalium* result was obtained: a positive female urine sample referred from an external laboratory, which had a *M. genitalium* load of less than 100 copies in the sample. This was detected by the reference assay; however, the value was near the cutoff, and the ResistancePlus MG assay returned a negative result. When this sample was retested in duplicate by the reference method, it resulted in a negative result and a positive result reflective of a sample with low bacterial load and at the threshold of the detection limit.

Among the 64 specimens positive for *M. genitalium* by the ResistancePlus MG assay, 63 (98.4%) were concordant with sequencing for 23S rRNA mutant detection, with a Kappa value of 0.97 (95% CI, 0.90 to 1.00) and sensitivity and specificity of 100% and 96.2%, respectively (Table 2).

Overall, 88% of the mutations represented in this cohort, as detected by Sanger sequencing, were A2058G or A2059G. Among the 5 mutation types detectable by the ResistancePlus MG assay, all except A2059C were present in this patient population and results corresponded to the Sanger sequencing result. Previously, it was shown that all 5 mutations are detectable with similar analytical sensitivities (21); however, detection of all these mutations and the clinical performance of the analyses would need to be determined with further studies and also in other populations. This study did not collect detailed symptoms from each patient, and, as such, further studies would need to be performed to evaluate the utility of *M. genitalium* and macrolide testing in asymptomatic patients. The data presented indicate that 63.1% of the specimens had macrolide resistance-associated mutations; however, these single nucleotide mutations confer high-level resistance to azithromycin and have been consistently associated with clinical failure of this drug (10, 24). Comparison to phenotypic resistance assay results was not possible in this study due to the well-established difficulty in culturing *M. genitalium*; however, phenotypic data have been correlated with resistance mutations (14).

The ResistancePlus MG assay performed extremely well against the reference methods utilized in our laboratory, and, unlike the sequencing method, this assay does not require specialized instrumentation and can be performed by routine diagnostic laboratories. It also offers the unique capability of simultaneous *M. genitalium* detection

and assessment of macrolide resistance. Patients infected with *M. genitalium* 23S rRNA mutants are predicted to fail treatment. This study aimed to evaluate the assay with consecutive samples sent to the laboratory and included a mixture of specimens from symptomatic and asymptomatic patients that had been sent to the laboratory for testing. Although the details of the individual patient symptoms were not available, the alarmingly higher prevalence of *M. genitalium* and resistance mutations detected in the male population, which consisted primarily of men from a sexual health clinic who were symptomatic with urethritis, highlights the importance of utilizing this assay for detection of *M. genitalium* and resistance testing to inform management of disease. This assay offers a considerable advantage for the rapid detection of macrolide-resistant strains and can be incorporated into diagnostic algorithms which can individualize antimicrobial therapy to ensure rapid delivery of agents to which the organism is susceptible. Where azithromycin is used as the first-line therapy, simultaneous availability of *M. genitalium* detection and detection of macrolide resistance mutations would allow clinicians to rapidly recall patients to provide a more appropriate second-line treatment in comparison to waiting for up to 4 weeks for test of cure or treatment failure. Where doxycycline rather than azithromycin is used as first-line therapy for sexually transmitted infection (STI) syndromes, patients with *M. genitalium* infection can be recalled for treatment with an antimicrobial based on the macrolide resistance profile. Macrolide-susceptible strains can be treated with azithromycin and macrolide-resistant strains with a quinolone such as moxifloxacin. Future assays that provide quinolone resistance data would assist in further refining clinical algorithms by identifying patients with dual-class resistance. Of note, 9% of *M. genitalium* strains at Melbourne Sexual Health Centre in Melbourne, Australia, currently have dual-class resistance (macrolide and quinolone), resulting in the need to use antimicrobials such as pristinamycin which have very limited availability outside Europe (25). Clinical algorithms such as this that incorporate resistance testing and individualize care have the potential to greatly improve microbial cure, to promote antimicrobial stewardship, and to reduce clinic visits and, ultimately, the spread of antibiotic-resistant bacteria in populations.

MATERIALS AND METHODS

Patient populations and sample types. Overall, 1,089 samples consecutively received over the course of 2 months (November to December 2015) were utilized for this evaluation. Specimens included 469 (344 from men and 125 from women) from the Melbourne Sexual Health Centre (MSHC), Victoria, Australia; 511 (12 from men and 499 from women) from the Royal Women's Hospital (RWH), Victoria, Australia; and 109 (32 from men and 77 from women) referred from external laboratories. The patient population from MSHC consisted primarily of symptomatic patients with NGU, cervicitis, and proctitis and/or PID, as well as of sexual contacts of *M. genitalium*-infected partners. The RWH samples were primarily from nonsymptomatic female patients presenting for contraceptive advice or for insertion of an intrauterine contraceptive device or referrals for medical and/or surgical termination of pregnancy, plus a small number of male partners referred for testing. Other samples were referred by external laboratories for diagnostic testing. Ethical approval for this study was granted by the Royal Women's Hospital Research Ethics Committee.

Sample processing, amplification, sequencing, and detection. Urine and flocked swab (Copan Diagnostic, Brescia, Italy) samples were processed and specimens extracted as described previously (10). Detection of *M. genitalium* by the ResistancePlus MG assay was performed in a blind manner with respect to the other results, and the data obtained were compared to the results of the laboratory-validated qPCR method targeting the 16S rRNA gene. Detection of macrolide resistance by the ResistancePlus MG assay was compared to detection of 23S rRNA mutations using Sanger sequencing (14). The ResistancePlus MG assay was performed simultaneously with the same extracted nucleic acid as was utilized for the reference method, according to the manufacturer's protocol (using the Beta version as previously described [21]). Briefly, an aliquot of 5 μ l extracted DNA (equivalent to 50 μ l of urine and 1/40 of the total swab specimen) was amplified for detection in a 20- μ l reaction volume; targets are selected across three fluorescent channels on a LightCycler 480 II real-time instrument (Roche Diagnostic, Indianapolis, IN, USA) for *M. genitalium* detection using the MgPa gene, 5 stacked 23S rRNA mutations, including A2058G, A2059G, A2058T, A2058C, and A2059C, and an internal control target; and data were analyzed using an analysis algorithm provided with the assay, as described previously (21).

Fisher's exact test was utilized to compare the data with respect to positivity and resistance between variables.

ACKNOWLEDGMENT

SpeeDx are the developer and manufacturer of the ResistancePlus MG assay evaluated and supplied the detection kits utilized for this study.

REFERENCES

1. Horner PJ, Taylor-Robinson D. 2011. Association of *Mycoplasma genitalium* with balanoposthitis in men with non-gonococcal urethritis. *Sex Transm Infect* 87:38–40. <https://doi.org/10.1136/sti.2010.044487>.
2. Tully JG, Taylor-Robinson D, Cole RM, Rose DL. 1981. A newly discovered mycoplasma in the human urogenital tract. *Lancet* i:1288–1291.
3. Cohen CR, Manhart LE, Bukusi EA, Astete S, Brunham RC, Holmes KK, Sinei SK, Bwayo JJ, Totten PA. 2002. Association between *Mycoplasma genitalium* and acute endometritis. *Lancet* 359:765–766. [https://doi.org/10.1016/S0140-6736\(02\)07848-0](https://doi.org/10.1016/S0140-6736(02)07848-0).
4. Deguchi T, Maeda S. 2002. *Mycoplasma genitalium*: another important pathogen of nongonococcal urethritis. *J Urol* 167:1210–1217. [https://doi.org/10.1016/S0022-5347\(05\)65268-8](https://doi.org/10.1016/S0022-5347(05)65268-8).
5. Jensen JS. 2004. *Mycoplasma genitalium*: the aetiological agent of urethritis and other sexually transmitted diseases. *J Eur Acad Dermatol Venereol* 18:1–11. <https://doi.org/10.1111/j.1468-3083.2004.00923.x>.
6. Taylor-Robinson D. 2002. *Mycoplasma genitalium*—an up-date. *Int J STD AIDS* 13:145–151. <https://doi.org/10.1258/0956462021924776>.
7. Uusküla A, Kohl PK. 2002. Genital mycoplasmas, including *Mycoplasma genitalium*, as sexually transmitted agents. *Int J STD AIDS* 13:79–85. <https://doi.org/10.1258/0956462021924695>.
8. Shahmanesh M, Moi H, Lassau F, Janier M; IUSTI/WHO. 2009. 2009 European guideline on the management of male non-gonococcal urethritis. *Int J STD AIDS* 20:458–464. <https://doi.org/10.1258/ijsa.2009.009143>.
9. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. 2015. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep* 64:1–137. <https://doi.org/10.15585/mmwr.r6404a1>.
10. Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, Vodstrcil LA, Jensen JS, Hocking JS, Garland SM, Bradshaw CS. 2015. Macrolide resistance and azithromycin failure in a *Mycoplasma genitalium*-infected cohort and response of azithromycin failures to alternative antibiotic regimens. *Clin Infect Dis* 60:1228–1236. <https://doi.org/10.1093/cid/ciu1162>.
11. Bradshaw CS, Jensen JS, Tabrizi SN, Read TR, Garland SM, Hopkins CA, Moss LM, Fairley CK. 2006. Azithromycin failure in *Mycoplasma genitalium* urethritis. *Emerg Infect Dis* 12:1149–1152. <https://doi.org/10.3201/eid1207.051558>.
12. Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR, Hakhu NR, Thomas KK, Hughes JP, Jensen NL, Totten PA. 2013. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. *Clin Infect Dis* 56:934–942. <https://doi.org/10.1093/cid/cis1022>.
13. Bradshaw CS, Chen MY, Fairley CK. 2008. Persistence of *Mycoplasma genitalium* following azithromycin therapy. *PLoS One* 3:e3618. <https://doi.org/10.1371/journal.pone.0003618>.
14. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. 2008. Azithromycin treatment failure in *Mycoplasma genitalium*-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. *Clin Infect Dis* 47:1546–1553. <https://doi.org/10.1086/593188>.
15. Gossé M, Lysvand H, Pukstad B, Nordbø SA. 2016. A novel SimpleProbe PCR assay for detection of mutations in the 23S rRNA gene associated with macrolide resistance in *Mycoplasma genitalium* in clinical samples. *J Clin Microbiol* 54:2563–2567. <https://doi.org/10.1128/JCM.01233-16>.
16. Twin J, Jensen JS, Bradshaw CS, Garland SM, Fairley CK, Min LY, Tabrizi SN. 2012. Transmission and selection of macrolide resistant *Mycoplasma genitalium* infections detected by rapid high resolution melt analysis. *PLoS One* 7:e35593. <https://doi.org/10.1371/journal.pone.0035593>.
17. Kristiansen GQ, Lisby JG, Schonning K. 2016. A 5' nuclease genotyping assay for identification of macrolide-resistant *Mycoplasma genitalium* in clinical specimens. *J Clin Microbiol* 54:1593–1597. <https://doi.org/10.1128/JCM.00012-16>.
18. Wold C, Sorthe J, Hartgill U, Olsen AO, Moghaddam A, Reinton N. 2015. Identification of macrolide-resistant *Mycoplasma genitalium* using real-time PCR. *J Eur Acad Dermatol Venereol* 29:1616–1620. <https://doi.org/10.1111/jdv.12963>.
19. Touati A, Peuchant O, Jensen JS, Bebear C, Pereyre S. 2014. Direct detection of macrolide resistance in *Mycoplasma genitalium* isolates from clinical specimens from France by use of real-time PCR and melting curve analysis. *J Clin Microbiol* 52:1549–1555. <https://doi.org/10.1128/JCM.03318-13>.
20. Tan LY, Walker SM, Lonergan T, Lima NE, Todd AV, Mokany E. 2017. Superior multiplexing capacity of PlexPrimers enables sensitive and specific detection of SNPs and clustered mutations in qPCR. *PLoS One* 12:e0170087. <https://doi.org/10.1371/journal.pone.0170087>.
21. Tabrizi SN, Tan LY, Walker S, Twin J, Poljak M, Bradshaw CS, Fairley CK, Bissessor M, Mokany E, Todd AV, Garland SM. 2016. Multiplex assay for simultaneous detection of *Mycoplasma genitalium* and macrolide resistance using PlexZyme and PlexPrime technology. *PLoS One* 11:e0156740. <https://doi.org/10.1371/journal.pone.0156740>.
22. Twin J, Taylor N, Garland SM, Hocking JS, Walker J, Bradshaw CS, Fairley CK, Tabrizi SN. 2011. Comparison of two *Mycoplasma genitalium* real-time PCR detection methodologies. *J Clin Microbiol* 49:1140–1142. <https://doi.org/10.1128/JCM.02328-10>.
23. Yoshida T, Deguchi T, Ito M, Maeda S, Tamaki M, Ishiko H. 2002. Quantitative detection of *Mycoplasma genitalium* from first-pass urine of men with urethritis and asymptomatic men by real-time PCR. *J Clin Microbiol* 40:1451–1455. <https://doi.org/10.1128/JCM.40.4.1451-1455.2002>.
24. Read TR, Fairley CK, Tabrizi SN, Bissessor M, Vodstrcil L, Chow EP, Grant M, Danielewski J, Garland SM, Hocking JS, Chen MY, Bradshaw CS. 2017. Azithromycin 1.5g over 5 days compared to 1g single dose in urethral *Mycoplasma genitalium*: impact on treatment outcome and resistance. *Clin Infect Dis* 64:250–256. <https://doi.org/10.1093/cid/ciw719>.
25. Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM, Jensen JS, Fairley CK, Tabrizi SN. Increasing macrolide and fluoroquinolone resistance in *Mycoplasma genitalium*. *Emerg Infect Dis*, in press.